Molecular Partners presented its bispecific Radio-DARPin platform at the Gordon Research Conference, highlighting advances in targeted radiopharmaceuticals
Executive summary: Molecular Partners showcased its bispecific Radio-DARPin candidates at the Gordon Research Conference on July 15, 2026. The demonstration underscores progress in targeted radiopharmaceuticals, potentially expanding therapeutic options and attracting partnership interest.
Who is involved: Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), its scientific team, and attendees at the Gordon Research Conference.
Likely next: The company may advance the Radio-DARPin candidates into further preclinical studies and seek collaborations with radiopharma firms.
The press release notes that Molecular Partners AG displayed its bispecific Radio-DARPin technology at the Gordon Research Conference on July 15, 2026. This showcases the company's progress in developing custom-built protein drugs that combine targeting potency with radioactive payloads. While the announcement is primarily a visibility event, it signals movement toward preclinical or clinical stages for a novel class of radiopharmaceuticals.
Timeline
- — European biotech mapped: 89 startups reshaping medicine (Sifted — EU startups)
- — Molecular Partners Showcases Bispecific Radio-DARPins at Gordon Research Conference (GlobeNewswire)
- — FDA grants Priority Review to Roche’s Gazyva/Gazyvaro for adults with primary membranous nephropathy (GlobeNewswire)
Analysis — what this means
Sectors affected
- radiopharmaceuticals
- targeted protein therapeutics
- molecular imaging
Historical parallels
- FDA approval of lutetium Lu 177 dotatate (Lutathera) for neuroendocrine tumors in 2018
- FDA approval of pembrolizumab (Keytruda) for melanoma in 2014
- EMA approval of lutetium Lu 177 vipivotide tetraxetan (Pluvicto) for prostate cancer in 2022